Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enoxaparin + aspirin is a combination therapy consisting of enoxaparin, a low molecular weight heparin anticoagulant, and aspirin (acetylsalicylic acid), an antiplatelet agent. This combination is used primarily to prevent complications from acute coronary syndromes such as unstable angina and heart attacks. Enoxaparin works by inhibiting factor Xa and IIa (thrombin), thereby reducing the formation of blood clots, while aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, preventing the formation of thromboxane A2 and thus platelet aggregation. The dual action provides enhanced protection against clot formation but also increases the risk of bleeding complications, particularly gastrointestinal bleeding. This regimen is often used in hospital settings for patients with acute coronary syndromes or at high risk for thromboembolic events[2][4][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on enoxaparin + aspirin.